| abstract |
1. The compound is preferably a C5a receptor antagonist having the following structure (IV):! ! where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 and R22 are separately and independently selected from the group including H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkylalkyl, heteroaryl, heteroalkyl , alkoxy, substituted alkoxy, aryloxy, substituted aryloxy, arylalkyloxy, substituted arylalkyloxy, acyloxy, substituted acyl xi, halogen, hydroxyl, nitro, cyano, acyl, substituted acyl, mercapto, alkylthio, substituted alkylthio, amino, substituted amino, alkylamino, substituted alkylamino, bis-alkylamino, substituted bis-alkylamino, cyclic amino, substituted cyclic amino, carbamoyl ( -CONH2), substituted carbamoyl, carboxyl, carbamate, alkoxycarbonyl, substituted alkoxycarbonyl, acylamino, substituted acylamino, sulfamoyl (-SO2NH2), substituted sulfamoyl, haloalkyl, haloalkyloxy, -C (O) H, trialkylsilyl and. ! 2. The connection according to claim 1,! where R1, R2, R3, R4 and R5 are separately and independently selected from the group consisting of H, alkyl, substituted alkyl, alkynyl, cycloalkyl, alkoxyl, substituted alkoxyl, acyloxy, halogen, nitro, cyano, acyl, alkylthio, substituted alkylthio , amino, substituted amino, alkylamino, substituted alkylamino, bis-alkylamino, cyclic amino, carbamoyl (-CONH2), acylamino and substituted acylamino,! either part! ! replaced by a part selected from the group consisting of! , and,! where R1, R2, R3, R4 and R5 are separately and independently |